Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia 1Hematologic Tumors 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Cyclosporine 3Methotrexate 2Imatinib Mesylate 2Dasatinib 2Cyclophosphamide 2ponatinib 1olverembatinib 1nilotinib 1fludarabine phosphate 1Whole-Body Irradiation 1Transplantation 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Mycophenolic Acid 1MK-8776 1Homoharringtonine 1Fentanyl 1Cytarabine 1Cord Blood Stem Cell Transplantation 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myeloid, Accelerated Phase × Homoharringtonine × Clear all
NCT00114959 2015-01-15

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Terminated
15 enrolled 6 charts
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myeloid, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡